The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Lipid zonation and phospholipid remodeling in nonalcoholic fatty liver disease
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) can progress from simple steatosis (i.e., nonalcoholic fatty liver [NAFL]) to nonalcoholic steatohepatitis (NASH), cirrhosis, and cancer. Currently, the driver for this progression is not fully understood; in particular, it is not known how NAFLD and its early progression affects the distribution of lipids in the liver, producing lipotoxicity and inflammation. In this study, we used dietary and genetic mouse models of NAFL and NASH and translated the results to humans by correlating the spatial distribution of lipids in liver tissue with disease progression using advanced mass spectrometry imaging technology. We identified several lipids with distinct zonal distributions in control and NAFL samples and observed partial to complete loss of lipid zonation in NASH. In addition, we found increased hepatic expression of genes associated with remodeling the phospholipid membrane, release of arachidonic acid (AA) from the membrane, and production of eicosanoid species that promote inflammation and cell injury. The results of our immunohistochemistry analyses suggest that the zonal location of remodeling enzyme LPCAT2 plays a role in the change in spatial distribution for AA‐containing lipids. This results in a cycle of AA‐enrichment in pericentral hepatocytes, membrane release of AA, and generation of proinflammatory eicosanoids and may account for increased oxidative damage in pericentral regions in NASH. Conclusion: NAFLD is associated not only with lipid enrichment, but also with zonal changes of specific lipids and their associated metabolic pathways. This may play a role in the heterogeneous development of NAFLD. (H epatology 2017;65:1165‐1180)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
van den Berg, R. A., Hoefsloot, H. C., Westerhuis, J. A., Smilde, A. K., & van der Werf, M. J. (2006) · BMC Genomics · doi:10.1186/1471-2164-7-142 · Cited by 2,450 · cited 1×
“11 latent structures discriminant analysis (OPLS-DA) models (25, 26) were constructed using SIMCA 14 (Umetrics, Sweden), following normalisation to the total ion count, and Pareto scaling (27).”
MethodA lipidomic analysis of nonalcoholic fatty liver disease
Puri, P., Baillie, R. A., Wiest, M. M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M. J., & Sanyal, A. J. (2007) · Hepatology · doi:10.1002/hep.21763 · Cited by 1,338
Lambert, J. E., Ramos–Roman, M. A., Browning, J. D., & Parks, E. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.11.049 · Cited by 1,069 · cited 2×
“Overall, we detected 34 different eicosanoids and lipid mediators including AAderived hydroxyeicosatetranoic acids (HETEs, 6), epoxyeicosatrienoic acids (EETs, 2), dihydroxyeicosatrienoic acids (DHETs, 3), prostaglandins (6); linoleic acid (LA)-derived hydroxyoctadecadienoic acids (HODEs, 2), epoxyoctadecaneoic acids…”
BackgroundThe plasma lipidomic signature of nonalcoholic steatohepatitis
Puri, P., Wiest, M. M., Cheung, O., Mirshahi, F., Sargeant, C., Min, H., Contos, M. J., Sterling, R. K., Fuchs, M., Zhou, H., et al. (2009) · Hepatology · doi:10.1002/hep.23229 · Cited by 655 · cited 14×
“(1) As a consequence, lipids are distributed differentially within the liver lobule; however, little is known about how the development and progression of NAFLD affects lipid zonation and metabolism.”
BackgroundInfluentialBiomarkers of NAFLD progression: a lipidomics approach to an epidemic
Gorden, D. L., Myers, D. S., Ivanova, P. T., Fahy, E., Maurya, M. R., Gupta, S., Min, J., Spann, N. J., McDonald, J. G., Kelly, S. L., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p056002 · Cited by 372
Research works printed but not linked: 37
- 2014, Pathological features of fatty liver disease, Gastroenterology, 147, 754, 10.1053/j.gastro.2014.07.056 · DOI · Paper page
- 2013, From NAFLD to NASH to cirrhosis‐new insights into disease mechanisms, Nat Rev Gastroenterol Hepatol, 10, 627, 10.1038/nrgastro.2013.149 · DOI · Paper page
- 2015, Fatty acid and glucose sensors in hepatic lipid metabolism: implications in NAFLD, Semin Liver Dis, 35, 250, 10.1055/s-0035-1562945 · DOI
- 2016, De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose, Biol Rev, 91, 452, 10.1111/brv.12178 · DOI · Paper page
- 2015, Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis, J Lipid Res, 56, 185, 10.1194/jlr.P055640 · DOI · Paper page
- 2013, Prediction of non‐alcoholic fatty‐liver disease and liver fat content by serum molecular lipids, Diabetologia, 56, 2266, 10.1007/s00125-013-2981-2 · DOI · Paper page
- 2014, Zonation of glucose and fatty acid metabolism in the liver: mechanism and metabolic consequences, Biochimie, 96, 121, 10.1016/j.biochi.2013.06.007 · DOI · Paper page
- 2011, MALDI imaging of lipid biochemistry in tissues by mass spectrometry, Chem Rev, 111, 6491, 10.1021/cr200280p · DOI · Paper page
- 2015, Current state and future challenges of mass spectrometry imaging for clinical research, Anal Chem, 87, 6426, 10.1021/acs.analchem.5b00416 · DOI
- 2013, Matrix‐assisted laser desorption ionization imaging mass spectrometry: in situ molecular mapping, Biochemistry, 52, 3818, 10.1021/bi301519p · DOI
- 2013, Differential intrahepatic phospholipid zonation in simple steatosis and nonalcoholic steatohepatitis, PLoS One, 8, e57165, 10.1371/journal.pone.0057165 · DOI
- 2009, Chemical imaging on liver steatosis using synchrotron infrared and ToF‐SIMS microspectroscopies, PLoS One, 4, e7408, 10.1371/journal.pone.0007408 · DOI
- 2009, In situ lipidomic analysis of nonalcoholic fatty liver by cluster TOF‐SIMS imaging, Anal Chem, 81, 2823, 10.1021/ac900045m · DOI · Paper page
- 2013, Hepatic‐specific activation of peroxisome proliferator‐activated receptor γ coactivator‐1β protects against steatohepatitis, Hepatology, 57, 1343, 10.1002/hep.26222 · DOI
- 2012, Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients, Hepatology, 56, 1751, 10.1002/hep.25889 · DOI · Paper page
- 2007, LMSD: LIPID MAPS structure database, Nucleic Acids Res, 35, D527, 10.1093/nar/gkl838 · DOI · Paper page
- 1998, Formation of lithiated adducts of glycerophosphocholine lipids facilitates their identification by electrospray ionization tandem mass spectrometry, J Am Soc Mass Spectrom, 9, 516, 10.1016/S1044-0305(98)00012-9 · DOI · Paper page
- 1957, A simple method for the isolation and purification of total lipids from animal tissues, J Biol Chem, 226, 497, 10.1016/S0021-9258(18)64849-5 · DOI · Paper page
- 2016, Myc expression drives aberrant lipid metabolism in lung cancer, Cancer Res, 76, 4608, 10.1158/0008-5472.CAN-15-3403 · DOI
- 2008, Visualization of GC/TOF‐MS‐based metabolomics data for identification of biochemically interesting compounds using OPLS class models, Anal Chem, 80, 115, 10.1021/ac0713510 · DOI · Paper page
- 2002, Orthogonal projections to latent structures (o‐PLS), J Chemometrics, 16, 119, 10.1002/cem.695 · DOI · Paper page
- 2011, imzML: imaging mass spectrometry markup language: a common data format for mass spectrometry imaging, Methods Mol Biol, 696, 205, 10.1007/978-1-60761-987-1_12 · DOI
- 2012, Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, World J Gastroenterol, 18, 2300, 10.3748/wjg.v18.i19.2300 · DOI · Paper page
- 2012, Laboratory animals as surrogate models of human obesity, Acta Pharmacol Sin, 33, 173, 10.1038/aps.2011.203 · DOI · Paper page
- 2015, Comprehensive metabolic profiling of age‐related mitochondrial dysfunction in the high‐fat‐fed ob/ob mouse heart, J Proteome Res, 14, 2849, 10.1021/acs.jproteome.5b00128 · DOI
- 2015, Adipose tissue fatty acid chain length and mono‐unsaturation increases with obesity and insulin resistance, Sci Rep, 5, 18366, 10.1038/srep18366 · DOI
- 2014, Role of adipose tissue in methionine–choline‐deficient model of non‐alcoholic steatohepatitis (NASH), Biochim Biophys Acta, 1842, 959, 10.1016/j.bbadis.2014.02.012 · DOI
- 2015, Mouse models of diet‐induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease, PLoS ONE, 10, e0127991, 10.1371/journal.pone.0127991 · DOI · Paper page
- 2011, Animal models in nonalcoholic steatohepatitis research: utility and clinical translation, Liver Int, 31, 440, 10.1111/j.1478-3231.2011.02463.x · DOI
- 2011, Animal models of nonalcoholic fatty liver disease, Nat Rev Gastroenterol Hepatol, 8, 35, 10.1038/nrgastro.2010.191 · DOI · Paper page
- 2010, Disruption of the 12/15‐lipoxygenase gene (Alox15) protects hyperlipidemic mice from nonalcoholic fatty liver disease, Hepatology, 52, 1980, 10.1002/hep.23928 · DOI
- 2012, Group IVA phospholipase A2 participates in the progression of hepatic fibrosis, FASEB J, 26, 4111, 10.1096/fj.12-205625 · DOI
- 2009, Alleviation of high‐fat diet‐induced fatty liver damage in group IVA phospholipase A2‐knockout mice, PLoS One, 4, e8089, 10.1371/journal.pone.0008089 · DOI
- 2011, Aberrant lipid metabolism disrupts calcium homeostasis causing liver endoplasmic reticulum stress in obesity, Nature, 473, 528, 10.1038/nature09968 · DOI · Paper page
- 2014, Diversity and function of membrane glycerophospholipids generated by the remodeling pathway in mammalian cells, J Lipid Res, 55, 799, 10.1194/jlr.R046094 · DOI · Paper page
- 2012, Disruption of phospholipid and bile acid homeostasis in mice with nonalcoholic steatohepatitis, Hepatology, 56, 118, 10.1002/hep.25630 · DOI · Paper page
- 2002, Kupffer cell aggregation and perivenular distribution in steatohepatitis, Mod Pathol, 15, 699, 10.1097/01.MP.0000019579.30842.96 · DOI
Cited by
Lipotoxicity and the gut-liver axis in NASH pathogenesis
Marra, F., & Svegliati-Baroni, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.014 · Cited by 847
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D., Seehawer, M., Zender, L., & Heikenwalder, M. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 616
Phospholipid Remodeling in Physiology and Disease
Wang, B., & Tontonoz, P. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114444 · Cited by 527
SpaceM reveals metabolic states of single cells
Rappez, L., Stadler, M., Triana, S., Gathungu, R. M., Ovchinnikova, K., Phapale, P., Heikenwalder, M., & Alexandrov, T. (2021) · Nature Methods · doi:10.1038/s41592-021-01198-0 · Cited by 390
Li, X., Wang, T., Huang, X., Li, Y., Sun, T., Zang, S., Guan, K., Xiong, Y., Liu, J., & Yuan, H. (2020) · Liver International · doi:10.1111/liv.14428 · Cited by 273
Lawitz, E. J., Coste, A., Poordad, F., Alkhouri, N., Loo, N., McColgan, B. J., Tarrant, J. M., Nguyen, T., Han, L., Chung, C., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.04.042 · Cited by 217
Acquisition of epithelial plasticity in human chronic liver disease
Gribben, C., Galanakis, V., Calderwood, A., Williams, E. C., Chazarra-Gil, R., Larraz, M., Frau, C., Puengel, T., Guillot, A., Rouhani, F. J., et al. (2024) · Nature · doi:10.1038/s41586-024-07465-2 · Cited by 142
Self-citationMetabolic Patterning on a Chip: Towards in vitro Liver Zonation of Primary Rat and Human Hepatocytes
Kang, Y. B., Eo, J., Mert, S., Yarmush, M. L., & Usta, O. B. (2018) · Scientific Reports · doi:10.1038/s41598-018-27179-6 · Cited by 122
Gai, Z., Visentin, M., Gui, T., Zhao, L., Thasler, W. E., Häusler, S., Hartling, I., Cremonesi, A., Hiller, C., & Kullak-Ublick, G. A. (2018) · Molecular Pharmacology · doi:10.1124/mol.117.111047 · Cited by 91
“Our data are consistent with a recent study demonstrating an increased hepatic expression of genes associated with eicosanoid synthesis in both diet- and genetic NAFLD mouse models (Hall et al., 2017).”
ResultTruong, X. T., & Lee, D. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0644 · Cited by 84
“The enrichment of enzymes responsible for generating some specific FA and their metabolites in a PV distribution in MASH provides further evidence to implicate lipid mediators in liver injury [74,105].”
Belenguer, G., Mastrogiovanni, G., Pacini, C., Hall, Z., Dowbaj, A. M., Arnes-Benito, R., Sljukic, A., Prior, N., Kakava, S., Bradshaw, C. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27923-z · Cited by 71
Self-citationBone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis
Vacca, M., Leslie, J., Virtue, S., Lam, B. Y. H., Govaere, O., Tiniakos, D., Snow, S., Davies, S., Petkevicius, K., Tong, Z., et al. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0214-9 · Cited by 60
Self-citationAzzu, V., Vacca, M., Kamzolas, I., Hall, Z., Leslie, J., Carobbio, S., Virtue, S., Davies, S. E., Lukasik, A., Dale, M., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101210 · Cited by 52
“Dysregulation of DNL and cholesterol synthesis in liver metabolism is a feature of NASH [11,12] and fibrogenesis [13].”
BackgroundSelf-citationFraser, D. A., Wang, X., Lund, J., Nikolić, N., Iruarrizaga-Lejarreta, M., Skjaeret, T., Alonso, C., Kastelein, J. J. P., Rustan, A. C., Kim, Y. O., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.12.004 · Cited by 41
Self-citationPerturbed liver gene zonation in a mouse model of non-alcoholic steatohepatitis
Zhou, Y., Zhao, Y., Carbonaro, M., Chen, H., Germino, M., Adler, C., Ni, M., Zhu, Y. O., Kim, S. Y., Altarejos, J., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155830 · Cited by 24
Saponara, E., Penno, C., Orsini, V., Wang, Z.-Y., Fischer, A., Aebi, A., Matadamas-Guzman, M. L., Brun, V., Fischer, B., Brousseau, M., et al. (2023) · The American Journal of Pathology · doi:10.1016/j.ajpath.2022.10.008 · Cited by 22
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R. M., Rogiers, V., Vanhaecke, T., & Boeckmans, J. (2022) · Biomedicines · doi:10.3390/biomedicines10010161 · Cited by 15
“Although lipid zonation seems lost in NASH [110], future research should clarify whether certain MAFLD phenotypes are of ‘pediatric’ or ‘adult’ nature and how oxygen tension and nutrient supply could modify lipogenesis in certain cell types.”
Background
Metadata
- Authors
- Hall, Z., Bond, N. J., Ashmore, T., Sanders, F., Ament, Z., Wang, X., Murray, A. J., Bellafante, E., Virtue, S., Vidal‐Puig, A., Allison, M., Davies, S. E., Koulman, A., Vacca, M., & Griffin, J. L.
- Venue
- Hepatology
- Published
- 2017-02-06
- Volume
- 65
- Issue
- 4
- Pages
- 1165-1180
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2553298154
- Cited by
- 211
- References
- 6
- FWCI
- 16.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.